Optimization of shRNA inhibitors by variation of the terminal loop sequence

Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research 2010-05, Vol.86 (2), p.204-211
Hauptverfasser: Schopman, Nick C.T., Liu, Ying Poi, Konstantinova, Pavlina, ter Brake, Olivier, Berkhout, Ben
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 211
container_issue 2
container_start_page 204
container_title Antiviral research
container_volume 86
creator Schopman, Nick C.T.
Liu, Ying Poi
Konstantinova, Pavlina
ter Brake, Olivier
Berkhout, Ben
description Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.
doi_str_mv 10.1016/j.antiviral.2010.02.320
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877570378</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354210003797</els_id><sourcerecordid>733300796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</originalsourceid><addsrcrecordid>eNqFkEtrGzEURkVpSZy0f6GdTclqXL1G0ixNyIuEBkq7FrLmDr5mZuRKsiH99ZGx4y6zunA5330cQr4xOmeUqR_ruZsy7jC6Yc5p6VI-F5x-IDNmNK9b2qqPZFZIVYtG8nNykdKaUqp0a87IeYkYo5WckcfnTcYR_7mMYapCX6XVr5-LCqcVLjGHmKrlS7VzEU9AXkGVIY44uaEaQthUCf5uYfLwmXzq3ZDgy7Fekj-3N7-v7-un57uH68VT7aXguQbOus4z0xjpnZOGecd6Ddwz5pZOyV6UF9oWOuo7rrpees14Q6X0IBjjSlySq8PcTQxlc8p2xORhGNwEYZus0brRVGjzLqmFEJTqdj9TH0gfQ0oReruJOLr4Yhm1e-V2bU_K7V65pdwW5SX59bhjuxyhO-XeHBfg-xFwybuhj27ymP5zXJlGNG3hFgcOirsdQrTJ495rhxF8tl3Ad495BfG5o4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733300796</pqid></control><display><type>article</type><title>Optimization of shRNA inhibitors by variation of the terminal loop sequence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Schopman, Nick C.T. ; Liu, Ying Poi ; Konstantinova, Pavlina ; ter Brake, Olivier ; Berkhout, Ben</creator><creatorcontrib>Schopman, Nick C.T. ; Liu, Ying Poi ; Konstantinova, Pavlina ; ter Brake, Olivier ; Berkhout, Ben</creatorcontrib><description>Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2010.02.320</identifier><identifier>PMID: 20188764</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Biological Products - genetics ; Biological Products - pharmacology ; Cell Line ; Cercopithecus aethiops ; Gene Knockdown Techniques - methods ; Gene Silencing ; Hairpin loop ; HIV-1 - drug effects ; HIV-1 replication ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Medical sciences ; Pharmacology. Drug treatments ; RNA, Small Interfering - genetics ; RNA, Small Interfering - pharmacology ; shRNA ; siRNA ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virus Replication - drug effects</subject><ispartof>Antiviral research, 2010-05, Vol.86 (2), p.204-211</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</citedby><cites>FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0166354210003797$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22685359$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20188764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schopman, Nick C.T.</creatorcontrib><creatorcontrib>Liu, Ying Poi</creatorcontrib><creatorcontrib>Konstantinova, Pavlina</creatorcontrib><creatorcontrib>ter Brake, Olivier</creatorcontrib><creatorcontrib>Berkhout, Ben</creatorcontrib><title>Optimization of shRNA inhibitors by variation of the terminal loop sequence</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.</description><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Biological Products - genetics</subject><subject>Biological Products - pharmacology</subject><subject>Cell Line</subject><subject>Cercopithecus aethiops</subject><subject>Gene Knockdown Techniques - methods</subject><subject>Gene Silencing</subject><subject>Hairpin loop</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 replication</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - pharmacology</subject><subject>shRNA</subject><subject>siRNA</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virus Replication - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtrGzEURkVpSZy0f6GdTclqXL1G0ixNyIuEBkq7FrLmDr5mZuRKsiH99ZGx4y6zunA5330cQr4xOmeUqR_ruZsy7jC6Yc5p6VI-F5x-IDNmNK9b2qqPZFZIVYtG8nNykdKaUqp0a87IeYkYo5WckcfnTcYR_7mMYapCX6XVr5-LCqcVLjGHmKrlS7VzEU9AXkGVIY44uaEaQthUCf5uYfLwmXzq3ZDgy7Fekj-3N7-v7-un57uH68VT7aXguQbOus4z0xjpnZOGecd6Ddwz5pZOyV6UF9oWOuo7rrpees14Q6X0IBjjSlySq8PcTQxlc8p2xORhGNwEYZus0brRVGjzLqmFEJTqdj9TH0gfQ0oReruJOLr4Yhm1e-V2bU_K7V65pdwW5SX59bhjuxyhO-XeHBfg-xFwybuhj27ymP5zXJlGNG3hFgcOirsdQrTJ495rhxF8tl3Ad495BfG5o4g</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Schopman, Nick C.T.</creator><creator>Liu, Ying Poi</creator><creator>Konstantinova, Pavlina</creator><creator>ter Brake, Olivier</creator><creator>Berkhout, Ben</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20100501</creationdate><title>Optimization of shRNA inhibitors by variation of the terminal loop sequence</title><author>Schopman, Nick C.T. ; Liu, Ying Poi ; Konstantinova, Pavlina ; ter Brake, Olivier ; Berkhout, Ben</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-e21ddc18584caa481ca1f7e2c11aba64f387299ed0cd26df4c7125044ce311263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Biological Products - genetics</topic><topic>Biological Products - pharmacology</topic><topic>Cell Line</topic><topic>Cercopithecus aethiops</topic><topic>Gene Knockdown Techniques - methods</topic><topic>Gene Silencing</topic><topic>Hairpin loop</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 replication</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - pharmacology</topic><topic>shRNA</topic><topic>siRNA</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schopman, Nick C.T.</creatorcontrib><creatorcontrib>Liu, Ying Poi</creatorcontrib><creatorcontrib>Konstantinova, Pavlina</creatorcontrib><creatorcontrib>ter Brake, Olivier</creatorcontrib><creatorcontrib>Berkhout, Ben</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schopman, Nick C.T.</au><au>Liu, Ying Poi</au><au>Konstantinova, Pavlina</au><au>ter Brake, Olivier</au><au>Berkhout, Ben</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimization of shRNA inhibitors by variation of the terminal loop sequence</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>86</volume><issue>2</issue><spage>204</spage><epage>211</epage><pages>204-211</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>Gene silencing by RNA interference (RNAi) can be achieved by intracellular expression of a short hairpin RNA (shRNA) that is processed into the effective small interfering RNA (siRNA) inhibitor by the RNAi machinery. Previous studies indicate that shRNA molecules do not always reflect the activity of corresponding synthetic siRNAs that attack the same target sequence. One obvious difference between these two effector molecules is the hairpin loop of the shRNA. Most studies use the original shRNA design of the pSuper system, but no extensive study regarding optimization of the shRNA loop sequence has been performed. We tested the impact of different hairpin loop sequences, varying in size and structure, on the activity of a set of shRNAs targeting HIV-1. We were able to transform weak inhibitors into intermediate or even strong shRNA inhibitors by replacing the loop sequence. We demonstrate that the efficacy of these optimized shRNA inhibitors is improved significantly in different cell types due to increased siRNA production. These results indicate that the loop sequence is an essential part of the shRNA design. The optimized shRNA loop sequence is generally applicable for RNAi knockdown studies, and will allow us to develop a more potent gene therapy against HIV-1.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>20188764</pmid><doi>10.1016/j.antiviral.2010.02.320</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0166-3542
ispartof Antiviral research, 2010-05, Vol.86 (2), p.204-211
issn 0166-3542
1872-9096
language eng
recordid cdi_proquest_miscellaneous_877570378
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - pharmacology
Biological and medical sciences
Biological Products - genetics
Biological Products - pharmacology
Cell Line
Cercopithecus aethiops
Gene Knockdown Techniques - methods
Gene Silencing
Hairpin loop
HIV-1 - drug effects
HIV-1 replication
Human immunodeficiency virus 1
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Medical sciences
Pharmacology. Drug treatments
RNA, Small Interfering - genetics
RNA, Small Interfering - pharmacology
shRNA
siRNA
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Virus Replication - drug effects
title Optimization of shRNA inhibitors by variation of the terminal loop sequence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A53%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimization%20of%20shRNA%20inhibitors%20by%20variation%20of%20the%20terminal%20loop%20sequence&rft.jtitle=Antiviral%20research&rft.au=Schopman,%20Nick%20C.T.&rft.date=2010-05-01&rft.volume=86&rft.issue=2&rft.spage=204&rft.epage=211&rft.pages=204-211&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2010.02.320&rft_dat=%3Cproquest_cross%3E733300796%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733300796&rft_id=info:pmid/20188764&rft_els_id=S0166354210003797&rfr_iscdi=true